41
Participants
Start Date
May 25, 2020
Primary Completion Date
September 30, 2021
Study Completion Date
April 4, 2023
Trastuzumab deruxtecan
"After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes.~In patients with hormone receptor (HR)-positive status (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) administration of endocrine therapy is not allowed.~In patients allocated in study cohort 5, administration of intrathecal therapy is not allowed"
Fundación Instituto Valenciano de Oncología (IVO), Valencia
Champalimaud Center for the Unknown, Lisbon
Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto), Porto
Institut Català d'Oncologica ICO Badalona, Badalona
Hospital del Mar, Barcelona
Institut Oncologic Baselga-Hospital Quiron Salud Barcelona, Barcelona
Hospital Universitario Reina Sofia, Córdoba
Institut Catala d'Oncologia ICO Hospitalet, L'Hospitalet de Llobregat
Hospital Clínico San Carlos, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario Ramon y Cajal, Madrid
IOB- Complejo Hospitalario Ruber Juan Bravo, Madrid
Hospital Universitario Virgen del Rocio, Seville
Hospital Clinico Universitario de Valencia, Valencia
Hospital Universitario Migue Servet, Zaragoza
Hospital Universitari Dexeus, Barcelona
Collaborators (1)
Daiichi Sankyo
INDUSTRY
MedSIR
OTHER